Similar articles

• Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.

  Duan SZ, Usher MG, Mortensen RM. Duan SZ, et al. Circ Res. 2008 Feb 15;102(3):283-94. doi: 10.1161/CIRCRESAHA.107.164384. Circ Res. 2008. PMID: 18276926 Review.
• PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.

  Remels AH, Langen RC, Gosker HR, Russell AP, Spaapen F, Voncken JW, Schrauwen P, Schols AM. Remels AH, et al. Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E174-83. doi: 10.1152/ajpendo.90632.2008. Epub 2009 May 5. Am J Physiol Endocrinol Metab. 2009. PMID: 19417127
• PPAR gamma: ally and foe in bone metabolism.

  Wahli W. Wahli W. Cell Metab. 2008 Mar;7(3):188-90. doi: 10.1016/j.cmet.2008.02.005. Cell Metab. 2008. PMID: 18316021
• Characterization of a negative feedback network between SUMO4 expression and NFkappaB transcriptional activity.

  Wang CY, Yang P, Li M, Gong F. Wang CY, et al. Biochem Biophys Res Commun. 2009 Apr 17;381(4):477-81. doi: 10.1016/j.bbrc.2009.02.060. Epub 2009 Feb 15. Biochem Biophys Res Commun. 2009. PMID: 19222990
• Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.

  Guo L, Tabrizchi R. Guo L, et al. Pharmacol Ther. 2006 Jul;111(1):145-73. doi: 10.1016/j.pharmthera.2005.10.009. Epub 2005 Nov 21. Pharmacol Ther. 2006. PMID: 16305809 Review.